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Strengths and limitation of this study
 ► This systematic review will be undertaken following 
the predefined population, exposure, comparator 
and outcome framework.
 ► All available databases, including six major data-
bases and threegrey literature databases, will be 
searched to obtain all eligible studies.
 ► The summarised results will improve our under-
standing of the current evidence of the possible 
association between vitamin D and herpesvirus 
infection/reactivation.
 ► The number of sufficient eligible studies may be in-
adequate, especially for some viruses that are hard-
er to diagnose; also, the included studies may not 
have an adequate quality of evidence to answer the 
research questions.
ABSTRACT
Introduction Human herpesviruses induce lifelong latent 
infections and may reactivate as the immune system 
deteriorates. Recent studies have suggested that vitamin 
D, an essential element of bone health, may have some 
effect of protecting against infections, but investigations of 
its potential to prevent herpesvirus infection or reactivation 
are limited. We will review the current literature examining 
vitamin D and the risk of herpesvirus infections or 
reactivation.
Methods and analysis Our systematic review will 
address two research questions: (1) Do deficient/
insufficient serum vitamin D levels increase the risk 
of herpesvirus infections and (2) Does vitamin D 
supplementation protect against herpesvirus infections? 
We will include only intervention studies with control 
groups, cohort studies and case-control studies. We 
will use subject headings and keywords to search for 
synonyms of ‘vitamin D’ and ‘herpesviruses’ (including 
herpes simplex virus type 1 and 2, varicella-zoster 
virus, cytomegalovirus, Epstein-Barr virus and human 
herpesviruses type 6, 7 and 8) in Medline, Embase, Global 
Health, Web of Science, Scopus and Cochrane Central 
Register of Controlled Trials, and the grey literature 
databases Open Grey, EThOS and BASE from inception to 
31 August 2019. References to the included articles and 
relevant systematic reviews will also be examined. Two 
reviewers will independently screen the study titles and 
abstracts, and examine the full texts to decide the final 
eligibility. They will independently extract data from the 
studies and assess bias using the Cochrane Collaboration 
approach. A third researcher will solve any discrepancies. 
The results will be narratively synthesised; if an adequate 
number of studies is included and the homogeneity 
between studies is acceptable, a meta-analysis will be 
performed. We will assess the quality of evidence using the 
Grading of Recommendations, Assessment, Development 
and Evaluation framework, and display the results in a 
summary of findings table.
Ethics and dissemination Ethical review is not required 
for a systematic review. We will publish the results in a 
peer-review journal. Any amendments to the protocol will 
be recorded in the supplementary section.
PROSPERO registration number CRD42019130153.
InTROduCTIOn
Rationale
Herpesviruses are a group of double-stranded 
DNA viruses that infect humans and some 
animals. After infecting their hosts, these 
viruses cannot be eradicated; instead, they 
establish latency and persist for life. As the 
host’s immunity declines, these viruses can 
reactivate to induce various symptoms. There 
are eight human herpesviruses (table 1).1 
Reactivation of herpesviruses may induce 
serious complications. For instance, herpes 
simplex virus 1 (HSV-1) can lead to herpetic 
keratitis, which is the major cause of blindness 
in high-income countries2; Epstein-Barr virus 
may induce nasopharyngeal cancer3 and vari-
cella-zoster virus would cause herpes zoster 
and postherpetic neuralgia, which increases 
financial burdens, especially for people older 
than aged 65 years.4 Consequently, investi-
gating immunomodulatory factors associated 
with infection or reactivation of this virus 
family is important.
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Table 1 List of human herpesviruses
Common name Abbreviation
Herpes simplex virus type 1 HSV-1
Herpes simplex virus type 2 HSV-2
Varicella-zoster virus VZV
Epstein-Barr virus EBV
Cytomegalovirus CMV
HHV-6 variant A HHV-6A
HHV-6 variant B HHV-6B
HHV-7 HHV-7
Kaposi’s sarcoma-associated HV KSHV
Vitamin D is mainly endogenously synthesised by the skin 
after sun exposure and can be supplied through dietary 
intake and supplementation. It plays an important role in 
absorbing calcium and phosphate, which are essential for 
bone health.5 Recently, some studies have indicated that 
vitamin D may have potential immunomodulatory effects 
associated with the regulation of antimicrobial peptides 
(AMPs).6 In previous cell studies, vitamin D induced gene 
expression of an AMP named cathelicidin. In response 
to pathogen exposure, immune cells such as monocytes 
or macrophages, upregulate vitamin D receptors and 
enzymes to increase the production of cathelicidin.7–9 In 
addition, evidence suggests that vitamin D has some effects 
on the adaptive immune system. Vitamin D suppresses 
CD4+ T helper (Th)1 lymphocytes and increases Th2 
lymphocytes, and it also intensifies the effect of regula-
tory T lymphocyte responses.10 11 Regarding the effects 
of vitamin D-associated AMPs on herpesviruses, a cell 
study indicated that cathelicidin decreased HSV-1 viral 
titres isolated from patients with keratoconjunctivitis12; 
furthermore, another cell study also showed that vitamin 
D supplementation reduced HSV-1 viral load and mRNA 
expression in HSV-1-infected cells.13
Vitamin D also shows some anti-infective potential in 
epidemiological studies. A meta-analysis using original 
patient data from 25 randomised controlled trials showed 
that among the general population, vitamin D supple-
mentation reduced the risk of acute respiratory infec-
tions.14 Furthermore, there is some evidence to suggest 
an anti-infective effect of vitamin D in specific patient 
groups, such as patients with chronic kidney disease 
(CKD), human immunodeficiency virus (HIV) or hepa-
titis C virus (HCV) infection. Among patients with CKD 
receiving dialysis, a case-control study indicated that the 
risk of herpes zoster reactivation was significantly lower 
in those who received vitamin D supplementation15; 
another meta-analysis also showed that patients with CKD 
with higher or normal serum vitamin D levels had a lower 
risk of infection.16 Among HIV-infected patients, lower 
serum vitamin D levels were also associated with a higher 
risk of clinical progression to AIDS and all-cause mortality 
in a cohort study,17 while vitamin D supplementation 
did not affect mortality, CD4 cell count or viral load.18 
For HCV-infected patients, serum vitamin D levels were 
inversely associated with the grade of liver inflammation 
and the stage of fibrosis,19 while no protective effect of 
vitamin D supplementation was seen in a meta-analysis 
of clinical trials.20 However, the effect of vitamin D on 
herpesvirus infection or reactivation in the general popu-
lation is unclear.
In this study, we will comprehensively review studies 
of the effect of serum vitamin D levels or the use of oral 
vitamin D supplementation on infection with or reactiva-
tion of any of the eight human herpesviruses.
OBjECTIvE
This review aims to explore the association between 
vitamin D and herpesviruses. The proposed systematic 
review will address two primary research questions:
1. Is serum vitamin D deficiency/insufficiency associated 
with an increased risk of infection with or reactivation 
of human herpesviruses?
2. Does oral vitamin D supplementation protect against 
infection with or reactivation of human herpesviruses?
METhOdS
This study protocol will be reported according to the 
Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols.21
Patient and public involvement
Patients and/or the public were not involved in this 
systematic review protocol.
Eligibility criteria
Study design and characteristics
To identify the possible causal association between vitamin 
D and herpesvirus infections, we will review observational 
studies, including cohort and case-control studies, and 
intervention studies with any type of control group, either 
placebo, active comparator or no treatment, including 
randomised or non-randomised controlled trials. Descrip-
tive studies, ecological studies, cross-sectional studies, case 
reports and case series will not be included. If a systematic 
review relevant to our topic is found, we will review its 
references.
Participants
Only human studies will be included in our review, and 
animal or cell studies will be excluded. Studies from all 
age groups or involving patients with any immune status 
are eligible.
Exposure
We have two exposures of interest for each research ques-
tion in our review. For the first research question, the 
exposures are deficient or insufficient serum vitamin D 
levels in the participants. We will include articles in which 
the serum vitamin D levels are identified as deficient or 
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Table 2 The normal range of serum vitamin D levels adapted in different studies
Study Deficiency (nmol/L) Insufficiency (nmol/L) Adequate (nmol/L)
Pearce and Cheetham26 <25 25–50 50–75
Institute of Medicine27 <30 30–50 ≥50
Holick et al28 <50 52.5–72.5
Hanley et al29 <25 25–75
1 nmol/L=0.4 ng/mL.
insufficient. Notably, no consensus exists about serum 
vitamin D levels, and different studies may use different 
definitions (table 2). If eligible studies provide original 
values for the serum 25(OH)D levels, we will define 
vitamin D deficiency as 25(OH)D<25 nmol/L and insuf-
ficiency as 25(OH)D in the range from 25 to 50 nmol/L 
in accordance with the standards of Public Health 
England.22
For the second research question, the intervention 
is oral vitamin D supplementation or oral vitamin D 
analogue treatment used for secondary hyperparathy-
roidism or osteoporosis (online supplementary table 1). 
We will exclude studies using topical vitamin D analogues, 
because their effects on systemic serum vitamin D levels 
are unknown.
Comparators
The comparator groups for vitamin D insufficiency and 
deficiency are those with sufficient serum vitamin D levels. 
For those receiving oral vitamin D supplementation or 
treatment, the comparators are those without vitamin D 
supplementation or treatment or receiving placebo or 
another active comparator, respectively.
Outcomes
The outcomes will be infection with or reactivation of 
all eight human herpesviruses listed in table 1. Infection 
with and reactivation of herpesviruses are defined using 
clinical or laboratory criteria. The clinical criteria include 
patients presenting with classical symptoms, for instance, 
the painful rash of herpes zoster, or a diagnosis recorded 
by physicians. Laboratory criteria include using labora-
tory techniques to confirm the diagnosis, such as evalu-
ation of the serum viral load by PCR. Studies reporting 
only serum antibodies against herpesviruses will not be 
included.
Information sources
We will search the following database from inception to 
31 August 2019: Medline (Ovid), EMBASE (Ovid), Web 
of Science, Scopus, Cochrane Library and Global Health 
(Ovid). To enhance the sensitivity of our search and 
reduce the risk of publication bias, we will also search grey 
literature databases such as Open Grey, BASE, EThOS 
and the clinical trials register at  ClinicalTrials. gov.
Search strategy
We will search for synonyms of ‘human herpesviruses’ 
and ‘vitamin D’ using both controlled vocabularies and 
keywords in each database. A search strategy in Medline 
(Ovid) is listed in online supplementary table 2. The 
subject headings will be modified for different databases. 
The results will be combined using the Boolean logic 
operator ‘AND’. For some database with limited search 
functions, such as single line search, keywords will be 
split into small sections to fulfil the requirement (online 
supplementary table 3). In addition to searching elec-
tronic databases, we will manually search for the refer-
ence lists of the included articles and relevant systematic 
reviews.
Study records
Data management
One researcher will import the search results from 
different databases into the citation management soft-
ware EndNote X9 (Clarivate Analytics, V.9.1/2019). 
Duplicated results will be identified and deleted.
Selection process
Two researchers will independently screen the titles 
and abstracts of all identified studies. We will obtain full 
texts of all studies fulfilling the review criteria, and the 
two researchers will screen all articles to establish their 
eligibility for inclusion. Any discrepancy in the reviewing 
process will be adjudicated by the third researcher.
Data collection process
Data extraction for the first three studies will be performed 
by two independent researchers to ensure the integrity of 
the process; then, one researcher will extract data from 
the remaining studies. If any data are missing or unclear, 
we will contact the authors for further clarification and 
information.
data items
We will summarise and extract data from the included 
studies using a Population, Exposure/Intervention, 
Comparator, Outcomes and Study characteristics frame-
work as follows:
1. Population: sample sizes of each study, inclusion or ex-
clusion criteria for the participants and demographic 
characteristics, such as sex, age or immune status
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2. Exposure 1: insufficient or deficit serum vitamin D lev-
els of the study participants. Exposure 2: oral vitamin 
D supplementation or vitamin D analogue
3. Comparator 1: sufficient serum vitamin D levels among 
the participants. Comparator 2: without vitamin D sup-
plementation or vitamin D analogue use.
4. Outcomes: definition of herpesvirus infection/reacti-
vation, that is, clinically diagnosed or laboratory-con-
firmed herpesvirus infections; the number of study 
subjects with the outcomes
5. Study characteristics: publication details (authors, 
publication year, country and journal), study designs, 
confounders measured, confounders adjusted and 
study results
Outcomes and prioritisation
The outcomes of the studies are herpesvirus infections 
or reactivation. The disease can be diagnosed either 
clinically or through laboratory confirmation. Some 
herpesvirus infections, such as herpes zoster, may lead 
to characteristic clinical symptoms, and some laboratory 
approaches, such as PCR, can detect the viral load, which 
can also be proof of herpesvirus infection/reactivation. 
Studies measuring serum antiherpesvirus antibodies 
will not be included, because antibodies detected in the 
absence of clinical symptoms cannot ascertain the timing 
of infection. Regarding the study results, our focus is on 
the incidence of herpesviruses infection or reactivation. 
We will report the outcome definition used for each study, 
and will extract data on the appropriate effect measure. 
The effect measures will include ORs for case-control 
studies and risk, rate or HRs for cohort studies or clinical 
trials. If studies report only continuous outcomes such as 
viral load, then we will summarise these using means or 
medians as appropriate.
Risk of bias in individual studies
We will assess the risk of bias from the included studies 
using a template form based on the Cochrane approach 
for trials and observational studies, and all relevant 
domains of bias will be assessed for different study types. 
For randomised controlled trials, we will evaluate bias 
due to the following sources: (1) random sequence 
generation; (2) allocation concealment; (3) blinding of 
participants, personnel or assessment; (4) incomplete 
outcome data and (5) selective reporting. For observa-
tional studies, we will consider bias due to the following 
sources: (1) confounding factors; (2) selection of partic-
ipants or controls; (3) differential and non-differential 
misclassification of the exposure or outcome; (4) reverse 
causation and (5) missing data (online supplementary 
table 4). A piloted form will be tested by applying it to 
extract data from the first three studies. To ensure the 
quality and consistency of the risk of bias assessment, the 
first three studies will be evaluated by two independent 
researchers. Then, one researcher will complete the eval-
uation of the remaining included studies. Any discrepan-
cies will be examined by the third researcher.
data synthesis and meta-bias (es)
We will comprehensively search different databases 
including grey literature databases to minimise bias in 
our search. We will use a narrative synthesis to summarise 
the data and results from the eligible studies included 
in our review. Since each herpesvirus subtypes have 
different pathogenic pathways, we will display the results 
separately by virus. If an adequate number of studies 
with acceptable homogeneity are included, a meta-anal-
ysis will be performed to integrate the study results. We 
will decide whether to use fixed-effects or random-effects 
models by considering the I2 value for heterogeneity; 
values >50% will be considered to represent substantial 
heterogeneity.23 If the number of included studies is 
sufficient, we will carry out subgroup analyses of subjects 
with baseline vitamin D status, intervention trials, study 
durations, different ages, immune statuses or latitude to 
explore sources of heterogeneity. A funnel plot will be 
used to present the distribution of studies and examine 
any possible publication bias.24 All statistical analyses will 
be performed by using STATA V.15.
Confidence in cumulative evidence
We will evaluate the quality of evidence using the Grading 
of Recommendations, Assessment, Development and Eval-
uations framework.25 We will evaluate the design and risk 
of bias across all included studies. Studies with significant 
effects, strong dose responses or that are well adjusted for 
plausible confounders will receive higher grades, whereas 
those with a higher risk of bias, inconsistency, indirect-
ness or imprecision will be downgraded. We will conclude 
the quality of evidence using a ‘Summary of Findings’ 
table and assign each outcome a quality rank of ‘high’, 
‘moderate’, ‘low’ or ‘very low’ for the level of confidence.
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